Jianpi Bushen, a Traditional Chinese Medicine Therapy, Combined with Chemotherapy for Gastric Cancer Treatment: A Meta-Analysis of Randomized Controlled Trials.
Jianpi Bushen, a Traditional Chinese Medicine Therapy, Combined with Chemotherapy for Gastric Cancer Treatment: A Meta-Analysis of Randomized Controlled Trials.
复制标题
健脾补肾联合化疗治疗胃癌：随机对照试验的荟萃分析
DOI：
10.1155/2018/4924279
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Ma M
中科院分区：
文献类型：
--
作者：
Chen Y;Zhang G;Chen X;Jiang X;Bie F;Yuan N;Wang Y;Hao X;Ma M
Objective.目的观察健脾补肾中药联合化疗治疗胃癌的临床疗效。方法.从开始到2017年10月，在PubMed、EMBASE、科克伦图书馆、MEDLINE、CNKI、万方数据信息网站和VIP中进行文献检索。确定了评价JPBS联合化疗效果的随机对照试验。主要报告的结局为KPS（Karnofsky体能状态）、临床疗效、免疫功能、血液系统和非血液系统。使用Review Manager 5.3（RevMan 5.3）进行数据分析，并对研究质量进行评价。结果共纳入26项研究，3098人。荟萃分析的结果表明，与单纯化疗相比，JPBS联合化疗治疗胃癌的结局更好。结论荟萃分析的证据表明，JPBS联合化疗对胃癌的治疗有积极的作用。然而，需要额外的严格设计和大样本随机对照试验来证实这种治疗的有效性和安全性。
Objective. To investigate the effects of Jianpi Bushen (JPBS), a traditional Chinese medicine that is used to invigorate the spleen and tonify the kidney, combined with chemotherapy for the treatment of gastric cancer. Methods. Literature retrieval was performed in PubMed, EMBASE, Cochrane Library, MEDLINE, CNKI, Wanfang Data Information Site, and VIP from inception to October 2017. Randomized controlled trials to evaluate the effects of JPBS combined with chemotherapy were identified. The primary reported outcomes were KPS (Karnofsky Performance Status), clinical curative efficiency, immune function, blood system, and nonhematologic system. Review Manager 5.3 (RevMan 5.3) was used for data analysis, and the quality of the studies was also appraised. Results. A total of 26 studies were included with 3098 individuals. The results of the meta-analysis indicated that treatment of gastric cancer with the combination of JPBS and chemotherapy resulted in better outcomes compared to chemotherapy alone. Conclusion. Evidence from the meta-analysis suggested that JPBS combined with chemotherapy has a positive effect on gastric cancer treatment. However, additional rigorously designed and large sample randomized controlled trials are required to confirm the efficacy and safety of this treatment.
影响因子：
1.9
作者：
Cianchi F;Indennitate G;Trallori G;Ortolani M;Paoli B;Macrì G;Lami G;Mallardi B;Badii B;Staderini F;Qirici E;Taddei A;Ringressi MN;Messerini L;Novelli L;Bagnoli S;Bonanomi A;Foppa C;Skalamera I;Fiorenza G;Perigli G
通讯作者：
Perigli G
基于胃癌患者化学疗法的不同分子靶向剂的功效和安全性：网络荟萃分析。
影响因子：
--
作者：
Ren Z;Sun J;Sun X;Hou H;Li K;Ge Q
通讯作者：
Ge Q